Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
23 oct. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
25 sept. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
Cara Therapeutics, Inc.
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46%...
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
03 août 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
02 août 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
24 juil. 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Jefferies Healthcare Conference
01 juin 2023 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
18 mai 2023 02h00 HE
|
Cara Therapeutics, Inc.
ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that...
Cara Therapeutics Reports First Quarter 2023 Financial Results
15 mai 2023 16h01 HE
|
Cara Therapeutics, Inc.
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as...